B0125 can reduce the release of excitatory neurotransmitters while increasing serotonin and epinephrine concentrations, effectively alleviating patients' pain symptoms. Compared to DPNP drugs currently available domestically and internationally, B0125 demonstrates higher efficacy rates and superior therapeutic outcomes, positioning it as a promising candidate to become the world's first multi-target drug for treating DPNP.
DPNP is a type of peripheral neuropathic pain caused by diabetes or prediabetes. It is the most common chronic complication of diabetes and one of the primary causes of diabetes-related disability. Therefore, developing more effective analgesics is an urgent clinical need.
Return to List
